VISX Receives FDA Approval for Treatment of Hyperopic Astigmatism.Business Editors, Health/Medical Writers SANTA CLARA, Calif.--(BW HealthWire)--Oct. 19, 2000 VISX, INCORPORATED (NYSE NYSE See: New York Stock Exchange Symbol:EYE) announced today that the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) has approved the use of its VISX STAR(TM) excimer laser systems as safe and effective for the treatment of hyperopic astigmatism. Commenting on the approval, Liz Davila, President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of VISX, said, "We are extremely pleased to add another FDA-approved indication to our product offering. The ability to treat hyperopic astigmatism on the VISX STAR laser systems will benefit our customers and their patients." VISX is the worldwide leader in the development of refractive refractive capacity to refract light. refractive error a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. laser technology. VISX systems are commercially available in the United States and markets worldwide. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion